New combo therapy aims to tame AML with precision radiation
NCT ID NCT03467386
First seen Feb 17, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This early-phase trial tests a new way to prepare adults with acute myeloid leukemia (AML) for a donor stem cell transplant. Instead of full-body radiation, it uses targeted radiation to the bone marrow and lymph nodes, followed by a drug called cyclophosphamide to prevent graft-versus-host disease. The main goal is to check safety and side effects in 56 participants whose AML is in remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.